Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 4/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069303 | 0.91 | AVPR1A (0.46) | AVPR1AMCHR1ESR2USP2SMN1; SMN2 | |
| SCHEMBL4072375 | 0.87 | AVPR1A (0.45) | AVPR1AMCHR1ESR2USP2SMN1; SMN2 | |
| SCHEMBL30623466 | 0.81 | AVPR1A (0.50) | AVPR1AMCHR1ESR2USP2SMN1; SMN2 | |
| SCHEMBL12701623 | 0.81 | AVPR1A (0.50) | AVPR1AMCHR1ESR2USP2SMN1; SMN2 | |
| SCHEMBL4067687 | 0.80 | AVPR1A (0.46) | AVPR1AMCHR1ESR2USP2SMN1; SMN2 | |
| SCHEMBL17586450 | 0.80 | AVPR1A (0.49) | AVPR1AMCHR1ESR2USP2SMN1; SMN2 | |
| SCHEMBL4074124 | 0.78 | AVPR1A (0.46) | AVPR1AMCHR1ESR2USP2SMN1; SMN2 | |
| SCHEMBL2159558 | 0.76 | AVPR1A (0.49) | AVPR1AESR2 | |
| SCHEMBL30743086 | 0.76 | NR1H2 (0.56) | AVPR1AESR2USP2SMN1; SMN2NR1H2 | |
| SCHEMBL30508320 | 0.76 | AVPR1A (0.49) | AVPR1AESR2USP2SMN1; SMN2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | BANYU PHARMACEUTICAL CO., INC. | 2011-01-20 | — | — | US | disclosed |
| EP-2272841-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | MC1R, MCHR2, MCHR1 | AVPR1A 29/4885MCHR1 3/4885KCNH2 2385/4885 |
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | AVPR1A 364/4885MCHR1 730/4885KCNH2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.